High throughput screening of 0.5 million compounds against CRAF using Alpha CETSAⓇ

Abstract

The cellular thermal shift assay (CETSA®) has increasingly been used in early drug discovery to provide a measure of cellular target engagement. Traditionally, CETSA has been employed for bespoke questions with small to medium throughput and has predominantly been applied during hit validation rather than in hit identification. Using a CETSA screen versus the kinase CRAF, we assessed 3 key questions: (1) technical feasibility – could the CETSA methodology technically be applied at truly high throughput scale? (2) relevance – could hits suitable for further optimisation be identified? (3) reliability – would the approach identify known chemical equity. Here, we describe the first large scale AlphaLISA SureFire based CETSA (Alpha CETSA) approach allowing us to screen a large library of almost 0.5 million compounds. We discuss the issues overcome in automating and executing the screen and describe the resulting screen output.

Keywords

• CETSA
• High-throughput screening
• Automation
• Cell-based assay
• CRAF
• Kinase